Home
    Webcasting
    Registration
    Accommodation
    Contact
     Home
     Scientific Committee
     Welcome Note
     Topics
     Faculty
     Satellite Symposia
         Webcasting
     Timetable & Program
         Friday, February 6, 2009
         Saturday, February 7, 2009
         Sunday, February 8, 2009
     Poster Presentation Schedule
         Group A
         Group B
         Poster Presentation Guidelines
         E-Posters
     Congress Prize
         Awardees
     CME
     Registration
     Invitation Letter
     Accommodation
     Accompanying Persons Program
     Sponsorship & Exhibition
     Sponsors
     General Information
         Before you travel ...
     Official Airline Network
     Italian Agent
     Contact Us
The 2nd World Congress on
Controversies in Urology (CURy)
Lisbon, Portugal, February 5- 8, 2009
 
  Friday, February 6, 2009 Print
Friday, February 6, 2009
 
08:30-10:00 Session 1
Hall A

LAPARASCOPIC SURGERY: NEW HORIZONS

Chairperson:
A. Alcaraz, Spain
        
08:30-09:15
Debate: Advancing future Minimally Invasive Surgery
 
Single Port Access (SPA)/Laparo-Endoscopic Single Sight (LESS) and its role in the era of Natural Orifice Transluminal Endoscopic Surgery (NOTES)
A. Alcaraz, Spain
E. Lima, Portugal
 
                   
09:15-10:00
Debate: Controversies in Laparoscopic Training formats with the prospective development of Minimally Invasive Surgery
 
Controversies in Teaching of Laparoscopy
T. Piechaud, France
 
Teaching Laparoscopy - The innovative approach
R. Bollens, Belgium
 
           
         
      
08:30-10:00 Session 2
Hall B PROSTATE CANCER: NEW INSIGHTS TO MINIMAL AND LOCALIZED DISEASE
WHO IS AT RISK? 
Chairpersons:
L. Boccon-Gibod, France
Z. Kirkali, Turkey
                               
Capsule:
Do we have the tools to determine who is at risk?
 
08:30-08:45
 
 
08:45-09:00
 
 
09:00-09:15
 
 
 
09:15-09:30
09:30-09:40 
 
09:40-10:00
Genetic markers for prostate cancer
Y. Fradet, Canada
 
Obesity and prostate cancer: A myth or a threat
J. Pinthus, Canada
 
Histopathological grading of prostate cancer detected by biopsy: How reliable is it?
Liliane Boccon-Gibod, France
 
Nomograms and predicting tables: Pros and cons
Pro: F. Montorsi, Italy
Con: V. Hupertan, France
 
Who is a candidate for active surveillance?
Do we have clinical tools that make active surveillance safe?
What should be the follow-up?
L. Boccon-Gibod, Frace
N. Fleshner, Canada
 
    
           
                    
10:00-10:30 Coffee Break and Poster Viewing
      
      
        
10:30-12:00 Session 3 
Hall A THE GREAT BLADDER WALL THICKNESS DEBATE:
TEARING IT DOWN, BRICK BY BRICK
Chairperson:
J. Heesakkers, The Netherlands
                                               
10:30-11:00
 
 
 
11:00-11:30
 
 
 
11:30-12:00
A thick bladder wall is caused by functional obstruction during voiding

Pro: J. Ruiz Cerda, Spain

Con: D. Robinson, UK
 

Bladder wall thickness is too difficult to measure

Pro: F. Cruz, Portugal
Con: M. Oelke, Germany
 

Bladder wall thickness in OAB: Does it have a role?

Pro: V. Khullar, UK

 Con: A. Tubaro, Italy
           
  
                    
10:30-12:00 Session 4
Hall B

ADVANCES IN THE MANAGEMENT OF METASTATIC RENAL CELL CANCER 

Chairperson:
C. Sternberg, Italy
   
Capsule: 
Has the approach to the treatment of metastatic kidney cancer changed?
 
Welcome & Introduction   
                
Case-based presentation:
 
Creating the Treatment Paradigm for Metastatic Renal Cell Cancer:
Does the Phase III evidences tell us what are the most appropriate options for our patients?
 
J. Bellmunt, Spain
V. Grunwald, Germany
P. Mulders, The Netherlands
J. Larkin, UK
    
         
        
  Combination vs. Sequential Therapy in Metastatic Renal Cell Cancer:
What does the evidences so far?
Pro: J. Bellmunt, Spain
       V. Grunwald, Germany
Con: P. Mulders, The Netherlands
       J. Larkin, UK
       
 
Q&A & Closing 
      
12:00-13:30 Session 5
Hall A

SATELLITE SYMPOSIUM:

HORMONE THERAPY FOR PROSTATE CANCER: EXPLORING CURRENT CONTROVERSIES

Chairperson:
F. Montorsi, Italy
        
Introduction
F. Montorsi, Italy
 
What is the added value of (neo) adjuvant hormone therapy?
J. Irani, France
 
Continuous or intermittent hormone therapy in advanced prostate cancer?
C. Schulman, Belgium
 
Quality of life of prostate cancer patients on hormone therapy: Do we care enough?
R. Berges, Germany
 
Discussion and take-home messages
F. Montorsi
 
Faculty and participants
 
              
           
13:30-14:30
Lunch Break and Poster Viewing
      
    
     
14:30-16:00 Session 6
Hall A KEY DECISIONS IN THE MANAGEMENT OF LUTS/BPH
Chairperson: F. Debruyne, The Netherlands
                                
Capsule:
Does the clinical practice of LUTS/BPH treatment differ from that of guidelines and text books?
 
14:30-15:00
 
 
 
15:00-15:30
 
 
 
15:30-16:00

Who to treat and who not to treat?

Update lecture: F. Desgrandchamps, France
Case discussion: Chairman & Audience
 
Are there still indications for minimally invasive and surgical treatment?
Update lecture: B. Parada, Portugal
Case discussion: Chairman & Audience
 
Medical therapy: How to select the right patient for the right treatment?
Update lecture: M. Speakman, UK 
Case discussion: Chairman & Audience
 
         
           
        
14:30-16:00 Session 7
Hall B

MEET THE EXPERTS:

AN INSTRUCTIVE CASE DISCUSSION ON BLADDER CANCER

Chairpersons:
A. Borkowski, Poland
A. Zlotta, Canada
                            
Capsule:
Are we able to suppress the invasive nature of non-muscle invasive bladder tumors?
 
14:30-14:45
 
 
 
 
 
14:45-15:00
15:00-15:15
Debate: Maintenance therapy
 
How many and for how long?
A. Zlotta, Canada
  
Is maintenance therapy indicated for CIS?
Pro: J. Palou, Spain
Con: Z. Kirkali, Turkey
 
               
15:15-16:00
Case discussion: High-grade T1 Bladder Cancer
 
The role of re-TUR
Prognostic factors
Optimizing efficacy of bladder irrigation
 
Presenter: A. Zlotta, Canada
 
Panel debaters:
Z. Kirkali, Turkey
O. Nativ, Israel
F. Witjes, The Netherlands
 
            
        
16:00-16:30
Coffee Break and Poster Viewing
 
    
      
16:30-18:00 Session 8
Hall A
SATELLITE SYMPOSIUM:
RECURRENT URINARY TRACT INFECTIONS: URO-VAXOM® A NEW ALTERNATIVE
Chairmen:
F. Cruz, Portugal
M. Dambros, Brazil
 

Opening

F. Cruz, Portugal

 

EAU guidelines on recurrent UTIs

K. Naber. Germany
 
Controversy discussion
Moderator: M. Dambros, Brazil
 
From science to clinical practice: The place of oral immunotherapy and Uro-Vaxom® in clinical practice
H.W. Bauer, Germany
 
From guidelines to clinical practice: What do we need?  What is missing?
K. Naber, Germany
 
Uro-Vaxom® future developments: An update on the clincal plan
G. Cozma, OM PHARMA, Switzerland
 
Closing
F. Cruz, Portugal
 
          
      
    
16:30-18:00 Session 9
Hall B

SATELLITE SYMPOSIUM:

TESTOSTERONE DEFICIENCY: A COMMON UNRECOGNIZED SYNDROME?

Chairperson:
C. Schulman, Belgium
 
Transversal European survey on testosterone deficiency diagnosis
TESTO Dia: The first results
J. Tostain, France
 
Why should we have to treat?
Testosterone and metabolic syndrome
M. Zitzmann, Germany
 
Testosterone and erectile dysfunction
P. Vendeira, Portugal
 
Testosterone and prostate cancer
Is there any link?
A. Martin Morales, Spain
 
New perspectives on testosterone treatment
V. Mirone, Italy
 
                   
18:00-18:30 CURy Happy Hour  

Home    Scientific Committee    Abstracts    Registration     Accommodation     Sponsorship & Exhibition    General Information    Contact Us   
Copyright © 2007 comtecmed.com. All rights reserved. Created by     WebStudio.co.il